IN2014KN02739A - - Google Patents

Info

Publication number
IN2014KN02739A
IN2014KN02739A IN2739KON2014A IN2014KN02739A IN 2014KN02739 A IN2014KN02739 A IN 2014KN02739A IN 2739KON2014 A IN2739KON2014 A IN 2739KON2014A IN 2014KN02739 A IN2014KN02739 A IN 2014KN02739A
Authority
IN
India
Prior art keywords
compliance
sustained
therapeutically
medicament
efficacy
Prior art date
Application number
Other languages
English (en)
Inventor
Monica Campisi
Cristian Guarise
Davide Renier
Original Assignee
Fidia Farmaceutici
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Farmaceutici filed Critical Fidia Farmaceutici
Publication of IN2014KN02739A publication Critical patent/IN2014KN02739A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00—Compositions of proteins; Compositions of derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IN2739KON2014 2012-05-31 2013-05-30 IN2014KN02739A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000173A ITPD20120173A1 (it) 2012-05-31 2012-05-31 "nuovo sistema di rilascio di proteine idrofobiche"
PCT/IB2013/054477 WO2013179258A1 (en) 2012-05-31 2013-05-30 New release system of hydrophobic proteins

Publications (1)

Publication Number Publication Date
IN2014KN02739A true IN2014KN02739A (ja) 2015-05-08

Family

ID=46321311

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2739KON2014 IN2014KN02739A (ja) 2012-05-31 2013-05-30

Country Status (14)

Country Link
US (1) US9731019B2 (ja)
EP (1) EP2854830B1 (ja)
JP (1) JP6247687B2 (ja)
KR (1) KR102090551B1 (ja)
CN (1) CN104349788B (ja)
CA (1) CA2874958C (ja)
EA (1) EA031390B1 (ja)
ES (1) ES2885764T3 (ja)
HK (1) HK1206993A1 (ja)
IN (1) IN2014KN02739A (ja)
IT (1) ITPD20120173A1 (ja)
MX (1) MX357799B (ja)
PT (1) PT2854830T (ja)
WO (1) WO2013179258A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201900003887A1 (it) 2019-03-18 2020-09-18 Fidia Farm Spa Sistemi di stabilizzazione e di rilascio controllato di farmaci instabili alla sterilizzazione
IT201900009933A1 (it) * 2019-06-24 2020-12-24 Fidia Farm Spa Composizioni farmaceutiche comprendenti derivati ammidici dell'acido ialuronico per uso nel trattamento di traumi ossei, in particolare in pazienti con problemi di osteopenia o osteoporosi

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US495774A (en) 1893-04-18 Island
IT1229075B (it) 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
DE3482812D1 (de) 1983-10-11 1990-08-30 Fidia Spa Fraktionen von hyaluronsaeure mit pharmazeutischer aktivitaet, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen.
US4582865A (en) 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4713448A (en) 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
IT1219587B (it) 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5827937A (en) 1995-07-17 1998-10-27 Q Med Ab Polysaccharide gel composition
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
ITPD980169A1 (it) * 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
IT1306679B1 (it) 1999-06-29 2001-10-02 Fidia Advanced Biopolymers Srl Uso dei derivati dell'acido ialuronico per la preparazione dicomposizoni farmaceutiche e biomateriali per la prevenzione della
US6645485B2 (en) 2000-05-10 2003-11-11 Allan R. Dunn Method of treating inflammation in the joints of a body
JP2008523129A (ja) * 2004-12-14 2008-07-03 フィディア・アドバンスト・バイオポリマーズ・ソシエタ・ア・レスポンサビリタ・リミタータ 二次元及び三次元ポリマー支持体の調製法
MY139088A (en) 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
ITPD20050056A1 (it) * 2005-03-02 2006-09-03 Fidia Farmaceutici Derivati ammidici del'acido ialuronico in osteoartrosi
ITPD20050207A1 (it) * 2005-07-07 2007-01-08 Fidia Farmaceutici Nuove composizioni farmaceutiche contenenti acido ialuronico e collagenas nel trattamento topico di ferite, ustioni ed ulcere
IT1402385B1 (it) 2010-09-09 2013-09-04 Fidia Farmaceutici Processo per la produzione di acido ialuronico in escherichia coli o bacillus subtilis

Also Published As

Publication number Publication date
CN104349788A (zh) 2015-02-11
MX2014014536A (es) 2015-02-24
EA031390B1 (ru) 2018-12-28
US20150290326A1 (en) 2015-10-15
PT2854830T (pt) 2021-09-02
ES2885764T3 (es) 2021-12-15
CN104349788B (zh) 2017-07-28
CA2874958C (en) 2023-02-14
JP6247687B2 (ja) 2017-12-13
EP2854830B1 (en) 2021-06-30
KR102090551B1 (ko) 2020-03-19
JP2015518042A (ja) 2015-06-25
KR20150016951A (ko) 2015-02-13
HK1206993A1 (en) 2016-01-22
ITPD20120173A1 (it) 2013-12-01
EA201491991A1 (ru) 2015-03-31
MX357799B (es) 2018-07-25
WO2013179258A1 (en) 2013-12-05
EP2854830A1 (en) 2015-04-08
CA2874958A1 (en) 2013-12-05
US9731019B2 (en) 2017-08-15

Similar Documents

Publication Publication Date Title
EA201991484A1 (ru) Лекарственные формы энзалутамида
PH12016500499A1 (en) Therapeutic polymeric nanoparticles and methods of making and using same
BR112015005878A2 (pt) nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas
EP2827837B8 (en) Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails
IN2012DN06720A (ja)
MX370543B (es) Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
HK1140940A1 (en) Titration of tapentadol
EP3513789A3 (en) Prophylactic and therapeutic agents for fgfr3 diseases
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
IN2014CN03123A (ja)
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
EA201390745A1 (ru) Активируемая пользователем автономная выполненная в едином корпусе система доставки лекарственного средства посредством ионофореза
WO2014164285A3 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
MX2015011775A (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
MX2014009892A (es) Combinaciones de inhibidor de histona desacetilasa y pazopanib y usos de las mismas.
MX2014005270A (es) Sistema de administracion vaginal con activiad osmotica.
GEP20156332B (en) Pyrazoles as crth2 antagonists
IN2014KN02739A (ja)
MX2015008171A (es) Formulacion que comprende agomelatina amorfa.
IN2014CN04222A (ja)
MX2015006779A (es) Proteina slurp-1 para usarse en el tratamiento de enfermedades oculares.
UA112488C2 (uk) Три(гетеро)арилпіразоли і їх застосування
EP2578232A4 (en) TREATMENT FOR AUTOIMMUN DISEASES AND ALLERGIC DISEASES
UA115307C2 (uk) Застосування лікарського засобу, що містить рекомбінантний лектин омели для лікування раку шкіри
MX2018004779A (es) Uso terapeutico de una solucion oftalmica acuosa esteril.